Evidence map›Paper›PMID 30820654›Full record

Trial reportEuropean journal of pediatrics2019

NTproBNP is a useful early biomarker of bronchopulmonary dysplasia in very low birth weight infants.

Paula Méndez-Abad, Pamela Zafra-Rodríguez, Simón Lubián-López, Isabel Benavente-Fernández

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Natriuretic peptides in bronchopulmonary dysplasia: a systematic review.Journal of perinatology : official journal of the California Perinatal Association · 2020
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Observational
  7. Review
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Urinary NT-proBNP as a potential noninvasive biomarker for screening of pulmonary hypertension in preterm infants: a pilot study.Journal of perinatology : official journal of the California Perinatal Association · 2020
    Article
  14. Review
  15. [Effect of asiaticoside on hyperoxia-induced bronchopulmonary dysplasia in neonatal rats and related mechanism].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Paula Méndez-AbadDepartment of Neonatology, Puerta del Mar University Hospital, Avenida Ana de Viya 21, 11009, Cádiz, Spain. pmendezab@gmail.com.ORCID http://orcid.org/0000-0003-2736-5109
Pamela Zafra-RodríguezDepartment of Neonatology, Puerta del Mar University Hospital, Avenida Ana de Viya 21, 11009, Cádiz, Spain.
Simón Lubián-LópezDepartment of Neonatology, Puerta del Mar University Hospital, Avenida Ana de Viya 21, 11009, Cádiz, Spain.
Isabel Benavente-FernándezDepartment of Neonatology, Puerta del Mar University Hospital, Avenida Ana de Viya 21, 11009, Cádiz, Spain.
Hospital Universitario Puerta del Mar · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bronchopulmonary dysplasia (BPD) is a severe complication of prematurity that impacts survival and neurodevelopment. Currently, no early marker exists which could help clinicians identify which preterm infants will develop BPD. Given the evidence that NTproBNP is elevated in children with BPD, we hypothesized that it could be used as an early marker of BPD development. We conducted a prospective cohort study including very low birth weight infants (VLBWI) admitted to our NICU between January 2015 and January 2017 in which we determined serial NTproBNP levels on days 1 and 3 and then weekly, until 49 days of life. A total of 101 patients were recruited (mean birth weight 1152 g (SD 247.5), mean gestational age 28.9 weeks (SD 1.9)). NTproBNP levels differed among infants who did and did not develop BPD from 14 to 35 days of life with the greatest difference on day 14 of life (non-BPD group (n = 86): 1155 (IQR 852-1908) pg/mL, BPD (n = 15): 9707 (IQR 3212-29,560) pg/mL; p = 0.0003). The presence of HsPDA did not account for higher levels of NTproBNP at day 14 (p = 0.165). We calculated an optimal cutoff point of 2264 pg/mL at 14 days of life (sensitivity 100%, specificity 86% and AUC 0.93).Conclusions: NTproBNP at 14 days of life could be used as an early marker of later BPD development in VLBWI. What is Known: • Children with BPD have elevated NTproBNP levels, which are related to the severity of BPD and the development of pulmonary hypertension. What is New: • NTproBNP at 14 days of life is higher in those who later develop BPD, regardless of the presence of hemodynamically significant patent ductus arteriosus. • A calculated cutoff point of 2264 pg/mL of NTproBNP at 14 days has a sensitivity of 100% and specificity of 86% in the prediction of BPD.

Indexed as

Infant, Very Low Birth WeightBiomarkersBronchopulmonary DysplasiaCase-Control StudiesDuctus Arteriosus, PatentFemaleHumansInfant, NewbornInfant, PrematureLongitudinal StudiesMaleNatriuretic Peptide, BrainPeptide FragmentsProspective StudiesSensitivity and SpecificityBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)BiomarkersBronchopulmonary dysplasiaPreterm infantPro-brain natriuretic peptide

Identifiers

PMID30820654
OpenAlexW2919833948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.